IRIS
MUTTI, LUCIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 354
NA - Nord America 204
AS - Asia 49
Totale 607
Salva come PNG Salva come JPEG
Nazione #
IE - Irlanda 330
US - Stati Uniti d'America 204
SG - Singapore 26
CN - Cina 23
IT - Italia 15
DE - Germania 4
FI - Finlandia 3
FR - Francia 2
Totale 607
Salva come PNG Salva come JPEG
Città #
Dublin 330
Boardman 47
New York 32
Los Angeles 24
Singapore 19
Ashburn 17
L’Aquila 7
Biella 3
Milan 3
Washington 3
Lappeenranta 2
Munich 2
Paris 2
Seattle 2
Berlin 1
Cassano Magnago 1
Council Bluffs 1
Forest City 1
Helsinki 1
Totale 498
Salva come PNG Salva come JPEG
Nome #
{CONFIRM} trial: what is the real efficacy of second-line immunotherapy in mesothelioma? 18
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology 18
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 17
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma 17
TNF-α determination in serum and pleural effusion in patients with lung cancer 17
Abemaciclib for malignant pleural mesothelioma 17
HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy 16
The function and clinical implication of YTHDF1 in the human system development and cancer 16
A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma 14
Neuro–Immune Interactions in Severe COVID-19 Infection 14
Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma 14
New standard for assessing asbestos exposure and its consequences? 14
European Respiratory Society Guideline on various aspects of quality in lung cancer care 14
Chemoprevention of asbestos-linked cancers: A systematic review 13
Genetic susceptibility to malignant mesothelioma and exposure to asbestos: The influence of the familial factor 13
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy 13
CDK4, CDK6/cyclin‐d1 complex inhibition and radiotherapy for cancer control: A role for autophagy 12
Sirtuin Family Members Selectively Regulate Autophagy in Osteosarcoma and Mesothelioma Cells in Response to Cellular Stress 12
Erionite and asbestos differently cause transformation of human mesothelial cells 12
Will antiangiogenic agents be a future for mesothelioma therapy? 12
Identification and Validation of Long Non-Coding RNA LCIIAR as a Biomarker in LUAD 12
Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point? 12
New agents in the management of advanced mesothelioma 12
The function and clinical implication of circular RNAs in lung cancer 12
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines 12
SV40 and human brain tumors [2] 11
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial 11
Association of SV40 with human tumours 11
P53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification 11
Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VII th Meeting of the International Mesothelioma Interest Group 11
What can independent research for mesothelioma achieve to treat this orphan disease? 11
Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia 10
MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications 10
Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications 10
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients 10
Over-Expression of Long Non-Coding RNA-AC099850.3 Correlates With Tumor Progression and Poor Prognosis in Lung Adenocarcinoma 10
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review 10
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma 10
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations 9
Comparison between plasma and serum osteopontin levels: Usefulness in diagnosis of epithelial malignant pleural mesothelioma 9
In vivo effect of human granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil GM-CSF receptors 9
When Ron met Tam in mesothelioma: All druggable for one, and one drug for all? 9
Recurrent chromosome 6 abnormalities in malignant mesothelioma 8
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 8
Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo 8
Simian Virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey 8
Intratumor microbiota as a novel potential prognostic indicator in mesothelioma 7
In arrayed ranks array technology in the study of mesothelioma steven 7
Preclinical Demonstrations of Synergistic Active Nutrient/Drug (and) Combination as a Potential Treatment for Malignant Pleural Mesothelioma 7
Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution 7
Editorial: Prognostic factors in non-small cell lung cancer 7
Taurolidine and oxidative stress: A rationale for local treatment of mesothelioma 7
Scientific Advances and New Frontiers in Mesothelioma Therapeutics 7
Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to Gefitinib 6
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma 6
Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma 6
Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism 5
A molecular epidemiology case control study on pleural malignant mesothelioma 4
Current treatment options and biology of peritoneal mesothelioma: Meeting summary of the first NIH peritoneal mesothelioma conference 4
Targeting hypoxic response for cancer therapy 3
Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer 3
Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation 3
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma 2
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts 2
Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma 2
Editorial: Editor's challenge: Dr. Luciano Mutti - what is the true impact of ICIs on survival in the treatment of thoracic malignancies? 2
High frequency of micronuclei in peripheral blood lymphocytes as index of susceptibility to pleural malignant mesothelioma 2
Gamma/delta T-lymphocytes in advanced pulmonary asbestosis 2
Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma (PLoS ONE (2017) 12:6 (e0180317) DOI: 10.1371/journal.pone.0085935) 2
Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma 2
Anti-CTLA-4 therapy for malignant mesothelioma 2
SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: A molecular epidemiologic case-control study 2
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma 2
Erratum: Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma (Genes, Chromosomes and Cancer (2000) 29 (173-179)) 2
Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas 2
Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage colony-stimulating factor 2
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study 2
Expression of glycoprotein 90K in human malignant pleural mesothelioma: Correlation with patient survival 2
ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe 2
Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines 2
Identification of overexpressed genes in malignant pleural mesothelioma 2
Malignant pleural mesothelioma: Current treatments and emerging drugs 2
Switching off malignant mesothelioma: Exploiting the hypoxic microenvironment 2
Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells 2
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: Imatinib mesylate with gemcitabine or pemetrexed 2
Estrogen receptor-β affects the prognosis of human malignant mesothelioma 2
Variations in aspecific bronchial reactivity elicited by methacholine in chronic bronchitis patients treated with doxofylline. Double blind cross-over study versus theophylline slow-release 1
Evaluation of a series of serum mesothelin in patients with pleural Malignant Mesothelioma 1
Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase 1
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells 1
Bortezomib inhibits nuclear factor-κB-dependent survival and has potent in vivo activity in mesothelioma 1
Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases 1
Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism 1
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals 1
Immunobiology and immune defence mechanisms of mesothelioma cells 1
Simian virus 40 and malignant mesothelioma (Review) 1
Current and prospective pharmacotherapies for the treatment of pleural mesothelioma 1
Therapies currently in Phase II trials for malignant pleural mesothelioma 1
BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment 1
Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis 1
Totale 708
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.600
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.600
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023395 0 0 0 0 0 0 0 53 327 0 4 11
2023/2024354 7 13 18 55 19 141 0 7 3 26 24 41
2024/20254 4 0 0 0 0 0 0 0 0 0 0 0
Totale 753